BONIVA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BONIVA (BONIVA).
Bisphosphonate that inhibits bone resorption via binding to hydroxyapatite and inhibiting osteoclast activity.
| Metabolism | Not metabolized; excreted unchanged by the kidneys. |
| Excretion | Renal: ~50-60% unchanged in urine; biliary/fecal: ~40-50% eliminated via feces, primarily as unchanged drug. |
| Half-life | Terminal half-life: 10-60 hours (clinical relevant); long terminal half-life (120-720 hours) due to slow dissociation from bone, supports weekly dosing. |
| Protein binding | ~85-90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd: 0.9-1.3 L/kg, indicating extensive distribution into bone and soft tissues. |
| Bioavailability | Oral: 0.63% (fasting state); reduced to ~0.4% with food. |
| Onset of Action | Oral: Reduction in bone turnover markers within 2-5 days; maximal effect on biomarkers in 3-6 months. |
| Duration of Action | Suppression of bone turnover persists 12-36 months after single oral dose due to prolonged bone binding; clinical effect lasts for duration of therapy. |
150 mg orally once monthly; 2.5 mg orally once daily also approved but less commonly used. Administer on empty stomach with plain water (6-8 oz) at least 60 minutes before first food, beverage, or other medications. Do not lie down for 60 minutes after administration.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated if CrCl < 30 mL/min. No adjustment for CrCl ≥ 30 mL/min. For CrCl 30-49 mL/min: avoid use due to lack of data; per FDA labeling, not recommended. For severe renal impairment (CrCl < 30): do not use. |
| Liver impairment | No specific adjustment required for hepatic impairment. Drug is not extensively metabolized by liver; pharmacokinetics unchanged in mild-to-moderate hepatic impairment. No data for severe hepatic impairment. |
| Pediatric use | Not approved for pediatric use. Safety and efficacy in patients < 18 years have not been established. |
| Geriatric use | No dose adjustment necessary based on age alone. Monitor renal function (CrCl) as elderly more likely to have decreased renal function; contraindicated if CrCl < 30 mL/min. Ensure adequate calcium and vitamin D intake. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BONIVA (BONIVA).
| Breastfeeding | Ibandronate is excreted in rat milk at concentrations 0.9 times maternal plasma levels. Human data: unknown. Risk to infant: potential for hypocalcemia and gastrointestinal irritation. Use during breastfeeding only if clearly needed and consider monitoring infant serum calcium. M/P ratio: not established in humans. |
| Teratogenic Risk | FDA Pregnancy Category C. In pregnant rats, intravenous ibandronate at doses ≥1 mg/kg/day caused fetal skeletal malformations, especially in the skull. In rabbits, no malformations at oral doses up to 10 mg/kg/day but maternal toxicity and reduced fetal weight occurred. Human data: insufficient. Theoretical risk of fetal skeletal abnormalities if used in pregnancy. Avoid use during pregnancy, especially in the second and third trimesters due to potential bone development interference. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to ibandronate or any component","Hypocalcemia","Inability to stand or sit upright for at least 60 minutes"]
| Precautions | ["Hypocalcemia must be corrected before therapy","Renal impairment: not recommended if CrCl <30 mL/min","Osteonecrosis of the jaw (ONJ)","Atypical femur fractures","Severe musculoskeletal pain"] |
| Food/Dietary | Food, beverages other than plain water, and medications significantly reduce absorption. Avoid all food, drink, and oral medications for at least 60 minutes after dose. For patient convenience, consider once-monthly dosing on the same day each month. Antacids, calcium or iron supplements, and mineral waters should be taken at least 60 minutes after BONIVA. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum calcium, phosphate, magnesium, and renal function prior to and during therapy. Assess for hypocalcemia, especially during pregnancy. Fetal monitoring: consider fetal ultrasound if exposure occurs in second/third trimester to evaluate skeletal development. No routine fetal monitoring required for short-term exposure. |
| Fertility Effects | In animal studies, no adverse effects on fertility in rats or rabbits at oral doses up to 10 mg/kg/day. In humans, no specific data; bisphosphonates may theoretically affect ovarian function due to calcium metabolism changes but no well-documented effect. Reversible menstrual irregularities reported in some women. Advise women of childbearing potential to use effective contraception. |
| Clinical Pearls | Administer on an empty stomach, first thing in the morning, with a full glass of plain water (6-8 oz). Patient must remain upright for at least 60 minutes after dosing to reduce esophageal irritation. Monitor serum calcium, phosphate, and vitamin D levels prior to initiation and periodically. Contraindicated in severe renal impairment (CrCl <30 mL/min). Discontinue if severe musculoskeletal pain occurs. |
| Patient Advice | Take tablet immediately after waking up with a full glass of plain water, at least 60 minutes before any food, drink, or other medications. · Do not chew, suck, or crush the tablet; swallow it whole. · Stay upright (sitting or standing) for at least 60 minutes after taking the tablet to prevent esophageal irritation. · If you miss a dose, skip it and resume the next morning; do not take two doses on the same day. · Ensure adequate intake of calcium and vitamin D as directed by your physician. · Report sudden thigh or groin pain, or jaw pain with loose teeth, as these may indicate rare adverse effects. |